PAIN THERAPEUTICS WKN: A2PGL8 ISIN: US14817C1071 Kürzel: SAVA Forum: Aktien Thema: Hauptdiskussion

64/65$ Widerstand und ~70$ Aufwärtstrend und EMA50 nächste Targets mMn. Wird spannend bleiben

🥲… dachte ihr seid schon alle Millionäre, die hier mitmischen! 😂

Bei einem Markt Kapital von 2 Milliarden wird es schwer Freunde zu finden die Millionen haben um den Preis zu beeinflussen...

Wenn Du 20 Deiner Freunde anschreibst und sagst, dass sie Casava kaufen sollen und die das auch mit 20 von ihren Freunden machen usw.... dann geht es hoch! Ansonsten bin ich mir bei den Damen und Herren in Übersee unsicher... leider! Meinetwegen kann es heute auch auf über 100,- EUR steigen! :)

Und habt ihr irgendwelche besonderen Nachrichten für die Woche mitbekommen ?

Was denkt ihr welche Richtung es ab 15:30 gehen wird ?

Good Morning in the morning

Guten Morgen ☀️ auf eine grüne Woche 🙏

Guten Morgen 🙃

Guten Morgen zusammen 😊

Guten Morgen ☕

Guten Morgen!

Gerne gerne!

Super Artikel, danke oxanabanana

https://www.marketbeat.com/instant-alerts/nasdaq-sava-consensus-analyst-rating-2021-09-2-3/

FRIDAY, SEPTEMBER 24, 2021 | MARKETBEAT Cassava Sciences logoCassava Sciences, Inc. (NASDAQ:SAVA) has been given a consensus recommendation of "Buy" by the five ratings firms that are presently covering the company, Marketbeat Ratings reports. Two research analysts have rated the stock with a hold recommendation and three have assigned a buy recommendation to the company. The average twelve-month price target among analysts that have covered the stock in the last year is $146.00. A number of equities research analysts recently commented on SAVA shares. B. Riley upped their price objective on Cassava Sciences from $111.00 to $145.00 and gave the company a "buy" rating in a report on Tuesday, August 3rd. Cantor Fitzgerald downgraded Cassava Sciences from an "overweight" rating to a "neutral" rating and set a $100.00 price target for the company. in a report on Thursday, July 15th. Jonestrading restated a "buy" rating and issued a $215.00 price target on shares of Cassava Sciences in a report on Friday, September 3rd. Zacks Investment Research upgraded Cassava Sciences from a "sell" rating to a "hold" rating in a report on Wednesday, August 11th. Finally, HC Wainwright increased their price target on Cassava Sciences from $97.00 to $124.00 and gave the stock a "buy" rating in a report on Tuesday, July 20th. Shares of NASDAQ:SAVA opened at $60.12 on Friday. The stock has a market capitalization of $2.41 billion, a price-to-earnings ratio of -162.48 and a beta of 0.97. The business's fifty day moving average price is $82.39 and its two-hundred day moving average price is $66.40. Cassava Sciences has a fifty-two week low of $6.70 and a fifty-two week high of $146.16.